Treatment-free Remission Accomplished With Dasatinib in Patients With CML
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 16 Jun 2019
Price : $35 *
At a glance
- Drugs Dasatinib (Primary) ; Imatinib
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms TRAD
- 04 Dec 2018 Results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 31 Oct 2018 Status changed from recruiting to active, no longer recruiting.
- 12 Dec 2017 Interim results (n=107) assesing correlation of RFS with IM discontinuation presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.